SCHEMBL6019803

SCHEMBL6019803

N#CCNC(=O)C(Cc1ccccc1)NC(=O)Nc1ccc([N+](=O)[O-])cc1

nearest known ligand 0.65

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
FPR1 P21462 4/20 0.65
FPR2 P25090 4/20 0.65
CTSS P25774 8/20 0.59
CTSK P43235 5/20 0.59
CTSL P07711 10/20 0.57
CTSB P07858 5/20 0.57
SSTR3 P32745 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6021469 0.92 FPR2 (0.60) FPR1FPR2CTSSCTSKCTSL
SCHEMBL6020933 0.91 FPR2 (0.62) FPR1FPR2CTSSCTSKCTSL
SCHEMBL6019623 0.90 CTSB (0.60) FPR1FPR2CTSSCTSKCTSL
SCHEMBL6019738 0.90 CTSS (0.57) FPR1FPR2CTSSCTSKCTSL
SCHEMBL6019938 0.87 CTSS (0.70) CTSSCTSKCTSLCTSB
SCHEMBL6021118 0.86 FPR2 (0.51) FPR1FPR2
SCHEMBL6021330 0.84 CTSS (0.64) FPR1FPR2CTSSCTSKCTSL
SCHEMBL22874402 0.84 FPR2 (0.68) FPR1FPR2
SCHEMBL16008095 0.84 FPR2 (0.68) FPR1FPR2
SCHEMBL6019605 0.83 CTSL (0.60) FPR1FPR2CTSSCTSKCTSL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060252813-A1 Apparatus for curing a composite laminate JERINI AG (DE) 2006-11-09 US claimed
WO-2004056755-A2 COMPOUNDS FOR THE INHIBITION OF NON-PROTEOLYTIC ENZYMES JERENI AG (DE) 2004-07-08 WO claimed
EP-1433778-A1 Use of nitriles as rotamase inhibitors Jerini AG (DE) 2004-06-30 EP claimed
EP-1433779-A1 Use of nitriles as inhibitors of non-proteolytic enzymes Jerini AG (DE) 2004-06-30 EP claimed
US-20060252813-A1 Apparatus for curing a composite laminate JERINI AG (DE) 2006-11-09 US disclosed
EP-1575903-A1 COMPOUNDS FOR THE INHIBITION OF ROTAMASES Jerini AG (DE) 2005-09-21 EP disclosed
WO-2004065353-A1 COMPOUNDS FOR THE INHIBITION OF ROTAMASES JERINI AG (DE) 2004-08-05 WO disclosed
WO-2004056755-A2 COMPOUNDS FOR THE INHIBITION OF NON-PROTEOLYTIC ENZYMES JERENI AG (DE) 2004-07-08 WO disclosed
EP-1433778-A1 Use of nitriles as rotamase inhibitors Jerini AG (DE) 2004-06-30 EP disclosed
EP-1433779-A1 Use of nitriles as inhibitors of non-proteolytic enzymes Jerini AG (DE) 2004-06-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060252813-A1 Apparatus for curing a composite laminate DHX29, HDHD5, DHRS9 FPR1 3451/4885FPR2 3247/4885CTSS 2720/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.